US 12227508
TGF-β inhibitors
granted A61PA61P11/00A61P13/00
Quick answer
US patent 12227508 (TGF-β inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61P, A61P11/00, A61P13/00, A61P15/00, A61P17/00